IPG1094 / Immunophage Biotech - LARVOL DELTA

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2024 ➔ Jul 2027 | Trial primary completion date: Jul 2024 ➔ Jul 2027

Enrollment open • Trial completion date • Trial primary completion date • Brain Cancer • Breast Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Strategic cooperation! AIMEFIE and Shanghai Gaobo Cancer Hospital affiliated to China Pharmaceutical University join hands again [Google translation] (Sohu.com) - "At the beginning of the new year, AIMEFIE, a company in Nanjing Biomedicine Valley, Jiangbei New District, has made another good news. It has reached a comprehensive strategic cooperation with Shanghai Gaobo Cancer Hospital of China Pharmaceutical University on the clinical research of the global innovative drug IPG1094....According to the agreement, Shanghai Gaobo Cancer Hospital will continue to promote the Phase II clinical trial of IPG1094 based on the existing clinical trials. Professor Li Jin, President, Chief Scientist and Chief Physician of Shanghai Gaobo Cancer Hospital affiliated to China Pharmaceutical University, will serve as the PI and be fully responsible for the Phase II clinical trial of IPG1094."

Commercial • Solid Tumor

Phase 1, Dose-escalation to Evaluate Safety,PK of IPG1094 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1/2 | N=60 | Not yet recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd

Metastases • New P1/2 trial • Brain Cancer • Breast Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer